	US 11,911,418 B2
	Treatment or prevention of gastrointestinal dysbiosis
Tor Lea, Oslo (NO); Charlotte Kleiveland, Vestby (NO); Karsten Kristiansen, Broby (DK); Benjamin Anderschou Holbech Jensen, Quebec (CA); Jacob Bak Holm, Copenhagen (DK); Ida Sogaard Larsen, Quebec (CA); and Morten Jacobsen, Moss (NO)
Assigned to Norges Miljo-Og Blovitenskapelige Universitet (NMBU), AS (NO); Sykehuset Ostfold HF, Gralum (NO); and University of Copenhagen, Copenhagen (DK)
Filed by Norges Miljo-Og Blovitenskapelige Universitet (NMBU), As (NO); Sykehuset Ostfold HF, Gralum (NO); and University of Copenhagen, Copenhagen (DK)
Filed on Apr. 12, 2022, as Appl. No. 17/718,798.
Application 17/718,798 is a continuation of application No. 16/635,428, granted, now 11,331,349, previously published as PCT/EP2018/071076, filed on Aug. 2, 2018.
Claims priority of application No. 1712459 (GB), filed on Aug. 2, 2017.
Prior Publication US 2022/0305062 A1, Sep. 29, 2022
Int. Cl. A61K 35/74 (2015.01); A61P 1/00 (2006.01)

CPC A61K 35/74 (2013.01) [A61P 1/00 (2018.01)]

15 Claims

1. A method for reducing the risk of gastrointestinal (GI) tract dysbiosis in a mammalian subject determined to be at risk of developing GI tract dysbiosis, said method comprising administering an effective, microbiota maintaining amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus as a pharmaceutically active ingredient to said mammalian subject.